AtriCure (ATRC) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $37.76 -5.95%
Financial Fact:
Research and development expenses: 8.27M
Today's EPS Names:
HFBL, PBHC, PBNK, More
Financial Fact:
Research and development expenses: 8.27M
Today's EPS Names:
HFBL, PBHC, PBNK, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q3 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $48.13 million.
GUIDANCE:
AtriCure sees FY2018 EPS of ($0.69)-($0.74), versus the consensus of ($0.69). AtriCure sees FY2018 revenue of $198-201 million, versus the consensus of $197.91 million.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- inTEST Corp (INTT) reported Q2 Revenue ; Offers Guidance
- Pinnacle Bank (PBNK) Tops Q2 EPS by 25c
- ExxonMobil Q2 profit falls short of forecasts, shares slide
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
